Expanded Access Program for Rexin-G Provides Genetic Medicine to Cancer Patients, First Revenues for Epeius Biotechnologies
SAN MARINO, CA - April 7 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation announced today that the Philippine Bureau of Food and Drugs (BFAD) has approved an Expanded Access Program for Rexin-G(TM), the lead product of Epeius Biotechnologies, developed for the treatment of metastatic cancer. Following the landmark approval of Rexin-G(TM) for the treatment of all solid tumors, the Expanded Access Program extends the clinical applications of the world's first targeted genetic medicine to many more cancer patients and enables Epeius Biotechnologies to recoup some of the costs of its ongoing clinical trials in Manila.
In a statement to the press, Dr. Erlinda Maria Gordon, M.D., Chairman, added: "We are pleased that the value of Rexin-G(TM) in the management of cancer is being appreciated by the international medical community, and that patients who are refractory to conventional chemotherapy now have additional options."
Ideally suited, by design, to function within the context of the human circulatory system, Rexin-G(TM) represents the first in a series of truly effective targeted genetic medicines that seek out and destroy metastatic cancer, without eliciting deleterious side effects or organ damage.
The unique Targeted Delivery System (TDS technology) engineered into Rexin-G(TM) carries a tumor-killing designer gene selectively to diseased tissues with such precision that a new term - "Pathotropic (or disease-seeking) Medicine" - was required to describe its properties. Rexin-G(TM) recently gained FDA Orphan Drug status as an effective treatment for pancreatic cancer in the United States, and is currently available in clinical trials at several American institutions, including Mayo Clinic in Minnesota.
Website: http://www.epeiusbiotech.com
Send2Press® is the originating wire service for this story. Terms of Use. © Epeius Biotechnologies Corporation. All trademarks acknowledged.
THE CONTENT OF THE ABOVE PRESS RELEASE WAS PROVIDED BY THE NEWS SOURCE ("Epeius Biotechnologies Corporation"), WHO IS SOLELY RESPONSIBLE FOR ITS ACCURACY. FOR QUESTIONS ABOUT THIS STORY CONTACT THE NEWS SOURCE AND NOT THIS WEBSITE.
Journalist Resources:
Download original press release as issued including media contact information for Epeius Biotechnologies Corporation.
Additional News Releases on Similar Topics:
|
Drugs and Pharmaceuticals
|
|
JOURNALISTS & WRITERS:
Subscribe to Send2Press® Daily News Summary by E-Mail
Follow Send2Press on Social Sites:
|